Acute Urticaria Clinical Trial
Official title:
A Phase III, Multi-center, Double Blind, Randomized, Active Controlled Clinical Trial to Evaluate the Non-Inferiority Comparing Cetirizine Injection 10 mg to Diphenhydramine Injection, 50 mg, for the Treatment of Acute Urticaria
This is a multicenter, parallel group, randomized, double-blind, active controlled, Phase III clinical study of cetirizine injection, 10 mg/mL, compared to diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent) with acute urticaria requiring treatment.
This was a multi-center, parallel group, randomized, double-blind, active controlled, Phase
III clinical trial of cetirizine injection 10 mg/mL versus diphenhydramine injection 50 mg/mL
(Benadryl or generic equivalent) in approximately 256 subjects who either presented to
Emergency Departments, hospitals, allergy clinics or Urgent Care Centers with acute
urticaria, or developed acute urticaria following allergen challenge at an Allergy Clinic.
Patients signed an informed consent and were evaluated for eligibility for inclusion to
treat. Eligible subjects were assessed for baseline characteristics, medical and surgical
histories, concomitant medications and given a brief physical exam.
Subjects were then randomized, in a 1:1 ratio, to blindly receive either cetirizine 10 mg/mL
injection or diphenhydramine 50 mg/mL injection.
Efficacy assessments included patient-rated severity of pruritus, physician assessments of
extent of urticaria/erythema, and sedation score. Subjects remained in the treatment center
for at least after the 1 hr assessment, after which they may have been discharged at the
physician's discretion.
Safety was monitored through the reporting of adverse events for up to 28 days following
treatments and by monitoring vital signs at planned intervals from admission into the
treating facility until readiness for discharge. After 24 and 48 hrs after discharge,
subjects were contacted by phone for follow-up questions regarding recurrence of symptoms,
new symptoms, additional medication taken, side effects from medication taken after
discharge, relapse requiring a return to treatment center, and return to normal activities.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02024152 -
Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg
|
Phase 1 | |
| Completed |
NCT02023164 -
Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria
|
Phase 3 | |
| Completed |
NCT02565680 -
Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency
|
Phase 2/Phase 3 | |
| Completed |
NCT02045524 -
A Pilot Single Dose Crossover Pharmacokinetics Study Of JDP-205 Injection, 10 mg, In Healthy Male And Female Volunteers
|
Phase 1 |